Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test

Brain Research

Volumn 1331, Issue , 2010, Pages 105-113

  Kalinichev, Mikhail ^a   Starr, Kathryn R ^a   Teague, Simon ^a   Bradford, Andrea M ^a   Porter, Rod A ^a   Herdon, Hugh J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anticonvulsant; Glycine; GlyT1; MEST; Transporter

Indexed keywords

2 CHLORO N [ALPHA (2 PIPERIDINYL)BENZYL] 3 TRIFLUOROMETHYLBENZAMIDE; ANTICONVULSIVE AGENT; DEXTRO SERINE; GLYCINE TRANSPORTER 1; GSK 931145; LAMOTRIGINE; LU AA 21279; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYL]SARCOSINE; ORG 25935; SB 710622; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; ELECTRIC SHOCK; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTICONVULSANTS; ELECTROSHOCK; GLYCINE; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; PHENOLS; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES;

ANIMALIA; RATTUS; RODENTIA; STRYCHNOS TOXIFERA;

EID: 77951297450     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2010.03.032     Document Type: Article

References (50)

1. Atkinson B.N., Bell S.C., De Vivo M., Kowalski L.R., Lechner S.M., Ognyanov V.I., Tham C.S., Tsai C., Jia J., Ashton D., and Klitenick M.A. ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. Mol. Pharmacol. 60 (2001) 1414-1420
2. Aubrey K.R., and Vandenberg R.J. N[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br. J. Pharmacol. 134 (2001) 1429-1436
3. Bergeron R., Meyer T.M., Coyle J.T., and Greene R.W. Modulation of N-methyl-d-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15730-15734
4. Betz H. Ligand-gated ion channels in the brain: the amino acid receptor superfamily. Neuron 5 (1990) 383-392
5. Chiamulera C., Costa S., and Reggiani A. Effect of NMDA- and strychnine-insensitive glycine site antagonists on NMDA-mediated convulsions and learning. Psychopharmacology 102 (1990) 551-552
6. Croucher M.J., and Bradford H.F. 7-Chlorokynurenic acid, a strychnine-insensitive glycine receptor antagonist, inhibits limbic seizure kindling. Neurosci. Lett. 118 (1990) 29-32
7. Croucher M.J., and Bradford H.F. The influence of strychnine-insensitive glycine receptor agonists and antagonists on generalized seizure thresholds. Brain Res. 543 (1991) 91-96
8. Cubelos B., Giménez C., and Zafra F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb. Cortex 15 (2005) 448-459
9. Danysz W., and Parsons C.G. Glycine and N-Methyl-D-Aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol. Rev. 50 (1998) 597-664
10. 3H]-Serine labels strychnine-insensitive glycine recognition sites of rat central nervous system. Life Sci. 46 (1990) 155-164
11. Depoortere R., Dargazanli G., Estenne-Bouhtou G., Coste A., Lanneau C., Desvignes C., Poncelet M., Heaulme M., Santucci V., Decobert M., Cudennec A., Voltz C., Boulay D., Terranova J.-P., Stemmelin J., Roger P., Marabout B., Sevrin M., Vigé X., Biton B., Steinberg R., Françon D., Alonso R., Avenet P., Oury-Donat F., Perrault G., Griebel G., George P., Soubrié P., and Scatton B. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 30 (2005) 1963-1985
12. Dixon W.J. Staircase bioassay: the up-and-down method. Neurosci. Biobehav. Rev. 15 (1991) 47-50
13. Dixon W.J., and Mood A.M. A method for obtaining and analyzing sensitivity data. J. Am. Stat. Assoc. 43 (1948) 109-126
14. Eulenburg V., Armsen W., Betz H., and Gomeza J. Glycine transporters: essential regulators of neurotransmission. Trends Biochem. Sci. 30 (2005) 325-333
15. Foster A.C., and Kemp J.A. HA-966 antagonizes N-methyl-D-aspartate receptors through a selective interaction with the glycine modulatory site. J. Neurosci. 9 (1989) 2191-2196
16. Ge J., Hamilton M., and Shahid D. The effects of Org 25935 on the extracellular levels of glycine in brain regions of freely moving rats using microdialysis. Br. J. Pharmacol. 133 (2001) 135
17. Halsey M.J., Little H.J., and Wardley-Smith B. Systemically administered glycine protects against strychnine convulsions, but not the behavioural effects of high pressure, in mice. J. Physiol. 408 (1989) 431-441
18. Hardingham G.E., Fukunaga Y., and Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5 (2002) 405-414
19. Homma S., Suzuki T., Murayama S., and Otsuka M. Amino acid and Substance P contents in spinal cord of cats with experimental hind-limb rigidity produced by occlusion of spinal cord blood supply. J. Neurochem. 32 (1979) 691-698
20. Javitt D.C. Glycine transport inhibitors for the treatment of schizophrenia: Symptom and disease modification. Curr. Opin. Drug Discov. Dev. 12 (2009) 468-478
21. Johnson J.W., and Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325 (1987) 529-531
22. Kimball A.W., Burnett W.T., and Doherty D.G. Chemical protection against ionizing radiation: I. sampling methods for screening compounds in radiation protection studies with mice. Radiat. Res. 7 (1957) 1-12
23. Koek W., and Colpaert F.C. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: relationship with phencyclidine-like behavioural effects. J. Pharmacol. Exp. Ther. 252 (1990) 349-357
24. Lapin I.P. Antagonism of l-glycine to seizures induced by l-kynurenine, quinolinic acid and strychnine in mice. Eur. J. Pharmacol. 71 (1981) 495-498
25. 50 values. J. Pharmacol. Toxicol. Methods 40 (1998) 81-85
26. Litchfield Jr. J.T., and Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96 (1949) 99-113
27. Löscher W., Wlaz P., Rundfeldt C., Baran H., and Honack D. Anticonvulsant effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)-HA-966 in amygdala-kindled rats. Br. J. Pharmacol. 112 (1994) 97-106
28. Martina M., Gorfinkel Y., Hlaman S., Low J.A., Periyalwar P., Schmidt C.J., and Bergeron R. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J. Physiol. 557 (2004) 489-500
29. Nong Y., Huang Y.Q., Ju W., Kalia L.V., Ahmadian G., Wang Y.T., and Salter M.W. Glycine binding primes NMDA receptor internalization. Nature 422 (2003) 302-307
30. Ohtani K., Tanaka H., Yoneda Y., Yasuda H., Ito A., Nagata R., and Nakamura M. In vitro and in vivo antagonistic activities of SM-31900 for the NMDA receptor glycine-binding site. Brain Res. 944 (2002) 165-173
31. Passchier J., Gentile G., Porter R., Herdon H., Salinas C., Jakobsen S., Audrain H., Laruelle M., and Gunn R.A. Identification and evaluation of [11C]GSK931145 as a novel ligand for imaging the type 1 glycine transporter with positron emission tomography. Synapse. 64 (2010) 542-549
32. Perry T.L., and Hansen S. Amino acid abnormalities in epileptic foci. Neurology 31 (1981) 872-876
33. Perry K.W., Falcone J.F., Fell M.J., Ryder J.W., Yu H., Love P.L., Katner J., Gordon K.D., Wade M.R., Man T., Nomikos G.G., Phebus L.A., Cauvin A.J., Johnson K.W., Jones C.K., Hoffmann B.J., Sandusky G.E., Walter M.W., Porter W.J., Yang L., Merchant K.M., Shannon H.E., and Svensson K.A. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 55 (2008) 743-754
34. Peterson S.L. Glycine potentiates the anticonvulsant action of diazepam and phenobarbital in kindled amygdaloid seizures of rats. Neuropharmacology 25 (1986) 1359-1363
35. Peterson S.L. Anticonvulsant drug potentiation by glycine in maximal electroshock seizures is mimicked by D-serine and antagonized by 7-chlorokynurenic acid. Eur. J. Pharmacol. 199 (1991) 341-348
36. Peterson S.L. 7-Chlorokynurenic acid antagonizes the anticonvulsant activity of -cycloserine in maximal electroshock seizures. Epilepsy Res. 13 (1992) 73-81
37. Peterson S.L., and Frye G.D. Glycine potentiates diazepam anticonvulsant activity in electroshock seizures of rats: possible sites of interaction in the brainstem. Brain Res. Bull. 18 (1987) 715-721
38. Peterson S.L., and Schwade N.D. The anticonvulsant activity of -cycloserine is specific for tonic convulsions. Epilepsy Res. 15 (1993) 141-148
39. Peterson S.L., Trzeciakowski J.P., Frye G.D., and Adams H.R. Potentiation by glycine of anticonvulsant drugs in maximal electroshock seizures in rats. Neuropharmacology 29 (1990) 399-409
40. Rahman S.S., Coulton S., Herdon H.J., Joiner G.F., Jin J., and Porter R.A. 1, 3-Diaminopropan-2-ol Sulfonamides as potent and selective inhibitors of the glycine transporter type 1. Bioorg. Med. Chem. Lett. 17 (2007) 1741-1745
41. Seiler N., and Sarhan S. Synergistic anticonvulsant effects of a GABA agonist and glycine. Gen. Pharmacol. Vasc. Syst. 15 (1984) 367-369
42. Seiler N., Sarhan S., Krogsgaard-Larsen P., Hjeds H., and Schousboe A. Amplification by glycine of the anticonvulsant effect of THPO, a GABA uptake inhibitor. Gen. Pharmacol. Vasc. Syst. 16 (1985) 509-511
43. Shim S.S., Hammonds M.D., and Kee B.S. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur. Arch. Psychiatry Clin. Neurosci. 258 (2008) 16-27
44. Singh L., Oles R.J., and Tricklebank M.D. Modulation of seizure susceptibility in the mouse by the strychnine-insensitive glycine recognition site of the NMDA receptor/ion channel complex. Br. J. Pharmacol. 99 (1990) 285-288
45. Singh L., Oles R.J., Vass C.A., and Woodruff G.N. A slow intravenous infusion of N-methyl-dl-aspartate as a seizure model in the mouse. J. Neurosci. Methods 37 (1991) 227-232
46. Smith G., Ruhland T., Mikkelsen G., Andersen K., Christoffersen C.T., Alifrangis L.H., Mørk A., Wren S.P., Harris N., Wyman B.M., and Brandt G. The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as GlyT-1 inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 4027-4030
47. Sur C., and Kinney G.G. Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission. Curr. Drug Targets 8 (2007) 643-649
48. Toth E., Lajtha A., Sarhan S., and Seiler N. Anticonvulsant effects of some inhibitory neurotransmitter amino acids. Neurochem. Res. 8 (1983) 291-302
49. Walker G.B., Hamilton W., Ge J., Bruin J., Shahid M., and Hill D. ORG 25935: a selective glycine uptake inhibitor. Schizophr. Res. 49 Suppl. 1 (2001) 97
50. Wlaz P., Baran H., and Loscher W. Effect of the glycine/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice. Eur. J. Pharmacol. 257 (1994) 217-225